3 news items
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
PPBT
1 Jun 24
, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219, CM24 and IM1240
Purple Biotech Reports First Quarter 2024 Financial Results
PPBT
21 May 24
cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
PPBT
14 Mar 24
that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management
- Prev
- 1
- Next